Ovarian Cancer Clinical Trial

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Summary

To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosed with serous ovarian cancer
Patients who have received no more than 3 previous platinum containing treatments and were progression free for at least 6 months following the end of the last platinum treatment
At least one lesion that is suitable for accurate repeated measurements

Exclusion Criteria:

Patients receiving any systemic anticancer chemotherapy, radiotherapy (except palliative) within two weeks from the last dose prior to study treatment
Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

162

Study ID:

NCT01081951

Recruitment Status:

Active, not recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 54 Locations for this study

See Locations Near You

Research Site
Stanford California, 94305, United States
Research Site
West Hollywood California, 90048, United States
Research Site
Orlando Florida, 32806, United States
Research Site
Indianapolis Indiana, 46202, United States
Research Site
Boston Massachusetts, 02114, United States
Research Site
Boston Massachusetts, 02215, United States
Research Site
New York New York, 10016, United States
Research Site
Portland Oregon, 97227, United States
Research Site
Parkville , 3050, Australia
Research Site
Randwick , 2031, Australia
Research Site
Brussels , 1090, Belgium
Research Site
Leuven , 3000, Belgium
Research Site
Namur , 5000, Belgium
Research Site
Wilrijk , 2610, Belgium
Research Site
Vancouver British Columbia, V5Z 4, Canada
Research Site
Hamilton Ontario, L8V 5, Canada
Research Site
Toronto Ontario, M4N 3, Canada
Research Site
Toronto Ontario, M5G 2, Canada
Research Site
Sherbrooke Quebec, J1H 5, Canada
Research Site
Quebec , G1R 2, Canada
Research Site
Brno , 625 0, Czechia
Research Site
Brno , 656 5, Czechia
Research Site
Hradec Kralove , 500 0, Czechia
Research Site
Olomouc , 775 2, Czechia
Research Site
Praha 2 , 120 0, Czechia
Research Site
Essen , 45147, Germany
Research Site
Frankfurt , 60590, Germany
Research Site
Hamburg , 20246, Germany
Research Site
München , 81675, Germany
Research Site
Solingen , 42653, Germany
Research Site
Genova , 16132, Italy
Research Site
Milan , 20141, Italy
Research Site
Monza , 20052, Italy
Research Site
Torino , 10126, Italy
Research Site
Chuo-ku , 104-0, Japan
Research Site
Fukuoka-shi , 811-1, Japan
Research Site
Matsuyama-shi , 791-0, Japan
Research Site
Minato-ku , 105-8, Japan
Research Site
Morioka-shi , 028-3, Japan
Research Site
Niigata-shi , 951-8, Japan
Research Site
Shinjuku-ku , 160-8, Japan
Research Site
Yamagata-shi , 990-9, Japan
Research Site
Yonago-shi , 683-8, Japan
Research Site
Amsterdam , 1066 , Netherlands
Research Site
Amsterdam , 1105 , Netherlands
Research Site
Nijmegen , 6525 , Netherlands
Research Site
Rotterdam , 3015 , Netherlands
Research Site
Ciudad de Panama , 2723, Panama
Research Site
Lima , LIMA , Peru
Research Site
Lima , LIMA , Peru
Research Site
Madrid , 08035, Spain
Research Site
Valencia , 46010, Spain
Research Site
Birmingham , B18 7, United Kingdom
Research Site
Coventry , CV2 2, United Kingdom
Research Site
Edinburgh , EH4 2, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

162

Study ID:

NCT01081951

Recruitment Status:

Active, not recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.